Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825901 | 0.79 | TDP1 (0.41) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL11382908 | 0.79 | TDP1 (0.36) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL2354887 | 0.79 | LMNA (0.36) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL27142591 | 0.78 | TDP1 (0.39) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL13761133 | 0.76 | TDP1 (0.50) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL4756190 | 0.76 | TDP1 (0.50) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL1604267 | 0.76 | TDP1 (0.50) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL9141650 | 0.74 | SLC1A3 (0.51) | TDP1SLC6A3MAPK1PPARAL3MBTL1 | |
| SCHEMBL11440142 | 0.73 | TDP1 (0.48) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL11439361 | 0.73 | TDP1 (0.48) | TDP1CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435071-B2 | Bryostatin compounds and methods of preparing the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-10-07 | — | — | US | disclosed |
| WO-2025133657-A1 | BIARYL-TYPE HETEROCYCLIC COMPOUNDS AND ANTI-BACTERIAL USES THEREOF | DEBRECENI EGYETEM (HU) | 2025-06-26 | — | — | WO | disclosed |
| US-20240116908-A1 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| US-11746105-B2 | Bryostatin compounds and methods of preparing the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210292309-A1 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-09-23 | — | — | US | disclosed |
| US-10947221-B2 | Bryostatin compounds and methods of preparing the same | THE BOARD OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190292172-A1 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-09-26 | — | — | US | disclosed |
| EP-3523296-A1 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | The Board of Trustees of the Leland Stanford Junior University (US) | 2019-08-14 | — | — | EP | disclosed |
| CN-109923110-A | Bryostatin compound and preparation method | 小利兰·斯坦福大学托管委员会 | 2019-06-21 | — | — | CN | disclosed |
| WO-2018067382-A1 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-04-12 | — | — | WO | disclosed |
| EP-1458703-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-1436371-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | Call, Krimhild (DE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003061550-A2 | NOVEL CATALYTIC ACTIVITIES OF OXIDOREDUCTASES FOR OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003053948-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2002099023-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-6452042-B1 | ELIMINATION OF AN ALCOHOL FROM A SUBSTITUTED MALONDIALDEHYDE ACETAL; THERMALLY STABLE, MORE REACTIVE CHEMICAL INTERMEDIATES FOR SUCH AS SYNTHESIS OF HETEROCYCLES | CREANOVA, INC. | 2002-09-17 | — | — | US | disclosed |
| EP-1012376-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | Blume, Hildegard (DE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998059108-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | BLUME, HILDEGARD (DE) | 1998-12-30 | — | — | WO | disclosed |
| WO-1994021265-A1 | ANTINEOPLASTIC AGENTS WITH IMPROVED EFFICIENCY | EISENBRAND GERHARD (DE) | 1994-09-29 | — | — | WO | disclosed |
| US-4634773-A | Thiazolidinylethylchlorocarbonates | POLAROID CORPORATION (US) | 1987-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746105-B2 | Bryostatin compounds and methods of preparing the same | PROKR1, PBK, PROKR2 | TDP1 3255/4885CHRM1 4447/4885AKR1A1 1234/4885 |
| US-10947221-B2 | Bryostatin compounds and methods of preparing the same | PROKR1, PBK, PROKR2 | TDP1 3255/4885CHRM1 4447/4885AKR1A1 1234/4885 |
| US-20210292309-A1 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | PROKR1, PBK, PROKR2 | TDP1 3255/4885CHRM1 4447/4885AKR1A1 1234/4885 |
| US-20190292172-A1 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | PROKR1, PBK, PROKR2 | TDP1 3255/4885CHRM1 4447/4885AKR1A1 1234/4885 |
| US-20240116908-A1 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | PROKR1, PBK, PROKR2 | TDP1 3255/4885CHRM1 4447/4885AKR1A1 1234/4885 |
| US-12435071-B2 | Bryostatin compounds and methods of preparing the same | PROKR1, PBK, PROKR2 | TDP1 3255/4885CHRM1 4447/4885AKR1A1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.